Melanotan II is not a pigmentation agent. It is a neuro-endocrine dual agonist that activates both MC1R and MC4R receptors simultaneously — thereby influencing both melanin synthesis and central neurological signaling. The ultimate research tool for photoprotection and UV-induced damage.
The peptide that reprograms the skin
In dermatological research, UV protection is almost always approached as an external matter: filters, blockers, antioxidants on the surface. Melanotan II breaks with that paradigm entirely. Rather than blocking UV radiation, it forces the cell itself to build endogenous protection — by activating melanocytes to increase production of eumelanin, the most photoprotective pigment the body knows.
"Sunscreen blocks the threat. Melanotan II teaches the cell to defend itself."
The dual mechanism of action
Melanotan II is a stabilized cyclic analog of the naturally occurring α-MSH (alpha-Melanocyte Stimulating Hormone). The cyclic ring structure dramatically extends half-life and enhances receptor affinity. In in-vitro models, it activates:
- MC1R (Melanocortin-1 Receptor) — primary melanin pathway in melanocytes
- MC4R (Melanocortin-4 Receptor) — central neurological signaling (appetite, libido, sympathetic tone)
- MC3R / MC5R — secondary affinity, smaller share in total response
It is precisely this dual-agonist signature that distinguishes Melanotan II from all previous photoprotection candidates — and what makes preclinical research on the peptide both dermatologically and neuro-endocrinologically relevant.
Melanotan II characteristics — Monospace Data Grid
| Parameter | Value |
|---|---|
| Synonym | MT-II · Ac-Nle-cyclo[Asp-His-DPhe-Arg-Trp-Lys]-NH₂ |
| Molecular formula | C₅₀H₆₉N₁₅O₉ |
| Molecular mass | 1024.18 g/mol |
| Amino acid count | 7 (cyclic lactam bridge) |
| Primary receptor affinity | MC1R · MC4R (dual agonist) |
| Half-life in-vitro | ~33 minutes (significantly longer than α-MSH) |
| Reconstitution | Bacteriostatic water · −20 °C |
| Stability lyophilized | ≥36 months at −20 °C |
| HPLC-purity Primal lot | ≥99% |
| Verification | Janoshik 3rd-party certificate per lot |
| Solubility | Fully soluble in water · BAC water · 0.9% NaCl |
| Storage post-reconstitution | ≤2-8 °C · max in chronic in-vitro models |
| Research domains | Photoprotection · neuroendocrinology · pigmentation models |
The most striking characteristic: with a half-life of ~33 minutes in vitro, Melanotan II has an ~30× longer active window than endogenous α-MSH (~1 minute). That is precisely the property that makes the peptide a reproducible research instrument.
Benefits from preclinical research
Preclinical data from in-vitro melanocyte cultures and controlled dermatological research models identify the following observable effects of Melanotan II administration:
- Increased eumelanin synthesis in cultured melanocytes — measurable pigment density increase within chronic in-vitro models
- Elevated MED (Minimal Erythemal Dose) in photoprotection models — cells tolerate significantly higher UV load before erythemal response occurs
- Reduction of UV-induced DNA damage — fewer cyclobutane pyrimidine dimers (CPDs) in cell cultures after controlled UV exposure
- Reduced ROS cascade post-UV — lower oxidative stress markers in melanocyte assays
- Neuro-endocrine response modulation via MC4R — secondary effect activating various research branches (appetite regulation, libido modulation, sympathetic tone)
- Faster recovery from UV-induced apoptosis in keratinocytes — photoprotective cellular programming remains activated longer
Results limited to in-vitro and in-vivo animal models. For in-vitro research application only — not for human or animal use.
Melanotan II in the Primal Peptides research instrument
Our Melanotan II batch (lot MT2-2026-009) is validated via:
- 01RP-HPLC with UV detection at 220 nm → ≥99% purity
- 02Mass spectrometry for molecular mass confirmation (1024.18 g/mol)
- 03Janoshik 3rd-party verification → public certificate per lot
- 04Vacuum-sealed glass vial · 10 mg lyophilized · strict −20 °C storage in our EU lab prior to dispatch
- 05Discrete EU dispatch · vacuum-sealed packaging · anonymous shipping label
Melanotan II is a potent dual agonist with central neurological effects. In research models, MC4R-mediated response variables (appetite modulation, libido shift, sympathetic activation, possible nausea in animal models) must be strictly controlled via baseline measurements and controlled exposure.
Legal disclaimer: Melanotan II is intended exclusively for IN-VITRO RESEARCH. Not for human use. Not for consumption. Not for cosmetic application.
The Primal Peptides standard
Every batch is independently validated. The Certificate of Analysis (COA) is the binding source of truth for each lot — publicly available, batch-specific, and generated by an independent third-party laboratory prior to dispatch. We publish no claims not supported per lot by the COA.
- 01RP-HPLC with UV detection → purity ≥ 98–99%
- 02Mass spectrometry → molecular mass confirmation
- 03Janoshik 3rd-party verification → public COA per lot
Our validation architecture is deliberately minimalist and rigorous: three reproducible assays, one independent verification, one public certificate. For the complete analytical dossier of your specific batch, consult the COA included with your shipment or via our public verification page.
Conclusion — The biological photoprotection architect
Melanotan II is not cosmetics and not a tan product. It is a razor-sharp research instrument that reprograms the cell itself for endogenous UV defense. For researchers studying photoprotection at the molecular level — not as a topical barrier but as cellular programming — Melanotan II is the most reproducible dual agonist the mainstream research pipeline offers.
Don't block the light. Teach the cell to answer it.
Melanotan II
Vertailustandardi suoraan Primal Peptides EU -laboratoriosta – tyhjiöpakattu, anonymisoitu ja huomaamattomasti lähetetty EU:n sisällä. Tiukat –20 °C säilytysprotokollat ennen lähetystä takaavat eräeheyden.
VAIN IN-VITRO-TUTKIMUSKÄYTTÖÖN · EI IHMISKÄYTTÖÖN · GMP-VAATIMUSTEN MUKAINEN SYNTEESI